A phase I trial of gamma-delta T cell immunotherapy candidate for the treatment of glioblastoma
Phase of Trial: Phase I
Latest Information Update: 20 Mar 2018
At a glance
- Drugs Allogeneic-gamma-delta-T-cell-therapy (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 20 Mar 2018 According to an Incysus media release, trial design will be presented at the 2018 CAR-T Congress USA Meeting.
- 11 Jan 2018 New trial record
- 09 Jan 2018 According to an Incysus Ltd. media release, the company has submitted an Investigative New Drug (IND) application with the US FDA to initiate this trial.